Investigational drug · Phase 3
Quabodepistat
Also called: OPC-167832, QBS
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Quabodepistat"
First trial start
2025
Oct 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Quabodepistat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rifampicin-Resistant Pulmonary Tuberculosis
- Multidrug-Resistant Pulmonary Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Quabodepistat" as an intervention, largest first.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07209761 · 532 participants (planned) · Start Oct 16, 2025 · Primary completion Sep 29, 2028
Drug: Bedaquiline; Quabodepistat and 3 more · For: Rifampicin-Resistant Pulmonary Tuberculosis; Multidrug-Resistant Pulmonary Tuberculosis
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 42 sites in all
- Study of Combinations of Novel Promising Drugs for Pulmonary TuberculosisPivotal-lookingNot yet recruiting
TASK Applied ScienceAcademic, hospital or other
NCT07773610 · 135 participants (planned) · Start Sep 25, 2026 · Primary completion Dec 30, 2027
Drug: TBAJ-587 50 mg; Pretomanid 200mg and 5 more · For: Tuberculosis, Pulmonary
Sites: Cape Town, South Africa
Newest research
PubMed records naming it or its code names, newest first.
- Activity of OPC-167832 against Mycobacterium abscessus and Mycobacterium chelonae: In vitro, intracellular, and in vivo assessment using a zebrafish infection model.
Chen S, Zhang C, Geng Z, et al. · Microb Pathog 2026
- Health-related quality of life measures in chronic pulmonary aspergillosis: a systematic review of psychometric validity.
Marghlani D, Singanayagam A, Ni ZM, et al. · Eur Respir Rev 2026
- Mechanism of the M. tuberculosis DprE1-DprE2 epimerase complex and inhibition by anti-tubercular drugs.
Gao S, Wu F, Zhang Y, et al. · Nat Chem Biol 2026
- Molecular engineering via C=N imine bridge and heterocycle modulation: Constructing red-emissive quinolinium probes for ratiometric and high-fidelity detection and imaging of bisulfite.
Wu CY, Liu N, Ma Z, et al. · Talanta 2026
- Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against Mycobacterium tuberculosis in an NHP model evaluated by [18F] FDG PET/CT and bacterial burden.
Via LE, Sarathy J, Weiner DM, et al. · Antimicrob Agents Chemother 2026
- Suppressed efficiency droop and size effect in InGaN micro-LEDs via engineered carrier confinement using Al-composition stepwise quantum barriers.
Zhang Y, Huang Y, Wang G, et al. · Opt Express 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Otsuka.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.